<h2>LY-CoV555 is a monoclonal antibody that can be used potentially in both the prevention and treatment of coronavirus</h2> </p><div> <!-- VIDEO --> <!-- PLAYER VIDEO --> <!-- BEGIN EMBED CODE BC player --> <!-- END EMBED CODE BC player --> <!-- END PLAYER VIDEO --> <!-- FINE VIDEO --> <!-- SOCIAL TOOLBAR -->
<p>By the end of June the <strong>first drug in the world</strong> able to <strong>fight the</strong> <strong>coronavirus</strong>. As reported by 'La Repubblica', the experimental medicine called <strong>LY-CoV555</strong> was administered in recent days to a group of patients hospitalized as part of the first study on a potential antibody treatment against <strong>SARS-CoV-2 virus</strong>. The results are expected in a very short time, just by the end of this month.
Among the medical centers involved are some of the most important hospitals in the United States of America, such as the NYU Grossman School of Medicine and the Cedars-Sinai of Los Angeles.
The process that led researchers from the pharmaceutical company Lilly to develop the antibody lasted only three months.
The antibody was identified by the Vaccine Research Center of the National Institute of Allergies and Infectious Diseases (NIAID), headed by Anthony Fauci, in collaboration with AbCellera, on a blood sample taken from one of the first American patients recovered from Covid-19.
LY-CoV555 is a monoclonal antibody designed to block the entry of coronavirus into human cells and is potentially usable in both the prevention and treatment of Covid-19.
Its effectiveness will be tested in the coming months both alone and in combination with other antibodies.
About that, Mark J. Mulligan, director of the Division of Infectious Diseases and Immunology, as well as director of the Vaccine Center at NYU Langone Health, said: “Such treatments promise to be effective countermeasures against coronavirus.”
Daniel Skovronsky, scientific director and president of Lilly Research Laboratories, he always added about these treatments: “They are also important for the groups most affected by the disease, such as the elderly and people with compromised immune systems who will not be able to undergo the vaccine”.
Then Skovronosky said: “Should LY-CoV555 prove to be part of the short-term solution for Covid-19, we want to be ready to make it available to patients as quickly as possible, already by the end of the year.”
VIRGILIO NEWS | 03-06-2020 15:45
<figure> <span> <a href="https://notizie.virgilio.it/coronavirus-quali-farmaci-stanno-sperimentando-1348980" title="Coronavirus, quali sono i farmaci che si stanno sperimentando" data-md5="f9d55bd48742f1b69d9209eb9af45f86"> <span class="ico-cont-lnc"> <svg role="img" class="ico-gallery"><use xlink:href="https://news.google.com/#ico-gallery"/></svg> </span> <img class="lazy" src="https://wips.plug.it/cips/notizie.virgilio.it/cms/2020/06/covid-sangue-pp.jpg?w=738&h=415&a=c" alt="Coronavirus, what are the drugs that are being tested"/> </a> <span class="fonte"> Photo source: Ansa </span> </span> <figcaption>Coronavirus, what are the drugs that are being tested</figcaption> </figure> </div><script async src="//platform.twitter.com/widgets.js" charset="utf-8"></script>